Patent Application
20110306564
1. Field of the Invention
The present invention relates to a solid composition, microparticles, a microparticle dispersion liquid, and manufacturing methods for these.
2. Related Background Art
In the recent development of new medical drugs, combinatorial chemistry methods have been adopted in synthesizing candidate compounds. Combinatorial chemistry is the art of adopting combinations to synthesize a wide variety of compounds in a short time at one time. Compounds obtained by this method have a solubility problem in many cases. That is, in many cases, even if a compound is found to have excellent physiological activity in itself, if the compound has a property of being difficult to dissolve in water, development of the compound is abandoned. Even with compounds obtained by extraction from natural products, various organic syntheses are carried out and structural optimization is performed to improve solubility. Some medical drugs already on the market are also low in solubility. With such drugs, a drug absorption amount varies within an individual patient and varies among individuals, and this places a large burden in terms of control of levels in blood, etc., on both a physician using a drug and a patient on whom the drug is used.
Microparticle formulations have received attention as a solution to the above problems. With a microparticle formulation, poorly soluble drug particles that are made no more than a micrometer in size are dispersed in water with stability. By using a microparticle formulation, a drug can be increased in absorption rate and amount in a living body. Reduction in variation of absorption amount within an individual patient and among individuals and increase in effective availability with respect to a dose can also be anticipated.
For improving solubility and absorbability of a poorly soluble drug, a drug formulation method such as nanoparticulation by means of pulverization, solid dispersion, or soluble complex formation is selected. However, drug microparticles have a high cohesive property, so that they cannot be stably dispersed in water without adding a proper dispersant. On the other hand, in solid dispersion, a drug in an amorphous state is present in a polymer-based material, so that the solubility in water can be temporarily increased, however, after a predetermined time, the solubility lowers according to precipitation of drug crystals.
Patent Document 1 discloses an invention relating to a solid composition with improved solubility and absorbability. In the invention disclosed in this Document, a poorly soluble drug, a polymer-based material, and a nonionic surfactant are dissolved in an organic solvent, and the solution is spray-dried to obtain a solid composition. In this invention, by dispersing the obtained solid composition in a liquid, microparticles no more than 1 μm maintaining the amorphous nature are obtained.
[Patent Document 1] International Publication WO96/19239
Problem to be Solved by the Invention
Patent Document 1 shows a comparative example 4 using sodium lauryl sulfate as an ionic surfactant. However, as a result of this comparative example 4, it is described that, “when sodium lauryl sulfate as an cationic surfactant was used, formation of microparticles no more than 1 μm was not observed.” Therefore, in claim 1 of Patent Document 1, the surfactant is limited to nonionic surfactants.
The present invention was made to solve the above-described problem, and an object thereof is to provide a solid composition, microparticles and a microparticle dispersion liquid etc., which contain a poorly soluble drug and has improved solubility and absorbability, and manufacturing methods for these.
Means for Solving the Problem
A solid composition manufacturing method of the present invention includes: (1) a dissolving step of dissolving a poorly soluble drug, polyvinylpyrrolidone, and sodium lauryl sulfate in a volatile organic solvent; and (2) a solid composition forming step of obtaining a solid composition as a residue by removing the organic solvent contained in the solution obtained through the dissolving step by evaporation.
A microparticle dispersion liquid manufacturing method of the present invention includes: (3) a water injecting step of immersing a solid composition obtained according to the solid composition manufacturing method in water; and (4) a microparticle dispersion liquid preparing step of forming microparticles from the solid composition immersed in water in the water injecting step by applying energy to the solid composition, and manufacturing a microparticle dispersion liquid containing the microparticles dispersed in water.
One container may be used throughout the entirety of the dissolving step, the solid composition forming step, the water injecting step, and the microparticle dispersion liquid preparing step. A container used in the steps before obtaining the residue and a container used in subsequent steps may be different from each other.
According to the present invention, in the dissolving step, a poorly soluble drug, polyvinylpyrrolidone, and sodium lauryl sulfate are dissolved in a volatile organic solvent. In the subsequent solid composition forming step, the organic solvent contained in the solution obtained through the dissolved step is removed by evaporation, and by the organic solvent removal, a solid composition as a residue is obtained. In a further subsequent water injecting step, the solid composition is immersed in water. Then, in the microparticle dispersion liquid preparing step, energy is applied to the solid composition immersed in water and the solid composition is made into microparticles, and a microparticle dispersion liquid containing the microparticles dispersed in water is manufactured.
In the above-described microparticle dispersion liquid preparing step, it is preferable that optical energy is applied to the solid composition to make the solid composition into microparticles, or vibration energy is applied to the solid composition to make the solid composition into microparticles, or energy is applied to the solid composition by stirring water to make the solid composition into microparticles.
A solid composition of the present invention is constituted of a poorly soluble drug, polyvinylpyrrolidone, and sodium lauryl sulfate being molecular-dispersed. Here, molecular-dispersion means uniform dispersion close to the molecular level. Microparticles of the present invention contain a poorly soluble drug, polyvinylpyrrolidone, and sodium lauryl sulfate. A microparticle dispersion liquid of the present invention is obtained by dispersing the microparticles of the present invention in water. A lyophilized material of the present invention is obtained by lyophilizing the microparticle dispersion liquid of the present invention. An orally administered formulation of the present invention contains the microparticles, the microparticle dispersion liquid, or the lyophilized material of the present invention. An injection formulation of the present invention contains a dispersion liquid obtained by resuspending the microparticles, the microparticle dispersion liquid, or the lyophilized material of the present invention in water. These can be manufactured by using the solid composition manufacturing method or microparticle dispersion liquid manufacturing method of the present invention, and have excellent solubility and absorbability.
The present invention can provide a solid composition, microparticles, and a microparticle dispersion liquid, etc., which contain a poorly soluble drug, polyvinylpyrrolidone, and sodium lauryl sulfate and is improved in solubility and absorbability.
The present invention also provides a means for solving the following problem of the conventional technique.
Paclitaxel which is one type of poorly soluble drug is also called taxol, and is known as an anti-tumor drug which effectively works against breast cancer, non-small-cell lung cancer, stomach cancer, esophageal cancer, head and neck cancer, ovary cancer, and uterine body cancer, etc., and is a compound frequently used in clinical practice. This compound is hardly dissolved in water (approximately 0.5 μg/mL at room temperature), so that a drug formulation device is essential for obtaining an injectable solution. At present, a paclitaxel formulation is sold as a mixed solution of ethanol and Cremophor EL (polyoxyethylene castor oil) in the proportion of 50 to 50, and when it is administered, it is mixed with a 5% glucose injection or normal saline and is drip-infused.
However, the above-described paclitaxel formulation contains a large amount of Cremophor EL as a surfactant, so that there is a risk that a patient who has a previous history of hypersensitivity to it will experience an anaphylactic shock. The paclitaxel formulation has a high ethanol concentration even after it is mixed with an infusion solution, so that there is a risk that a patient who is alcohol-hypersensitive will experience alcohol poisoning.
Published Japanese Translation of PCT Application No. H10-502921 discloses an invention relating to stable oil-in-water emulsion containing taxines (taxol) and a manufacturing method for the same. In the invention disclosed in this Document, paclitaxel is dissolved in an alcohol solution, and to this, an equivalent amount of oil is added and mixed until the solution becomes transparent, and then alcohol is removed by rotary evaporation or evaporation under a nitrogen flow. Then, the paclitaxel oil solution obtained through this removal is dispersed in water by using a surfactant, and accordingly, stable oil-in-water emulsion is formed.
Japanese Patent No. 3656550 discloses an invention relating to a drug composition containing cyclodextrin and taxoid. In the invention disclosed in this Document, paclitaxel and cyclodextrin derivative are dissolved in alcohol, and then alcohol is evaporated, and accordingly, a dried solid is obtained.
In the invention disclosed in Published Japanese Translation of PCT Application No. H10-502921, emulsion is formed by using oil, so that the amount to be used for the surfactant is reduced. However, paclitaxel is also a compound with low solubility to oil, so that there is a high possibility that crystals precipitate from the oil emulsion, and this poses a problem in safety.
In the invention disclosed in Japanese Patent No. 3656550, a cyclodextrin derivative is used as a dispersant which replaces the surfactant. However, the amount of cyclodextrin necessary for dispersion is remarkably large as 25 times to 400 times the amount of paclitaxel. The use of such a large amount of additive poses a problem in safety.
To solve the above-described problems, the present invention provides a paclitaxel solid composition, paclitaxel microparticles, and a paclitaxel microparticle dispersion liquid, etc., improved in stability and safety, and manufacturing methods for these.
A paclitaxel solid composition manufacturing method of the present invention includes: (1) a dissolving step of dissolving paclitaxel and a dispersion stabilizer in a volatile organic solvent; and (2) a solid composition forming step of obtaining a paclitaxel solid composition as a residue by removing the organic solvent contained in the solution obtained through the dissolving step by evaporation. Here, it is preferable that the dispersion stabilizer contains polyvinylpyrrolidone and sodium lauryl sulfate.
A paclitaxel microparticle dispersion liquid manufacturing method of the present invention includes: (3) a water injecting step of immersing a paclitaxel solid composition obtained according to the paclitaxel solid composition manufacturing method of the present invention in water; and (4) a microparticle dispersion liquid preparing step of forming microparticles from the paclitaxel solid composition immersed in water in the water injecting step by applying energy to the paclitaxel solid composition, and manufacturing a microparticle dispersion liquid containing the microparticles dispersed in water.
One container may be used throughout the entirety of the dissolving step, the solid composition forming step, the water injecting step, and the microparticle dispersion liquid preparing step. A container to be used in steps before the residue is obtained and a container to be used in subsequent steps may be different from each other.
According to the present invention, in the dissolving step, paclitaxel and a dispersion stabilizer are dissolved in a volatile organic solvent. In the subsequent solid composition forming step, the organic solvent contained in the solution obtained through the dissolving step is removed by evaporation, and by the organic solvent removal, a paclitaxel composition is obtained as a residue. In the further subsequent water injecting step, the paclitaxel solid composition is immersed in water. Then, in the microparticle dispersion liquid preparing step, energy is applied to the paclitaxel solid composition immersed in water and the paclitaxel solid composition is made into microparticles, and a microparticle dispersion liquid containing the microparticles dispersed in water is manufactured.
In the above-described microparticle dispersion liquid preparing step, it is preferable that optical energy is applied to the paclitaxel solid composition to make the paclitaxel solid composition into microparticles, or vibration energy is applied to the paclitaxel solid composition to make the paclitaxel solid composition into microparticles, or energy is applied to the paclitaxel solid composition by stirring water to make the paclitaxel solid composition into microparticles.
A paclitaxel solid composition of the present invention is constituted of paclitaxel and a dispersion stabilizer being molecular-dispersed. Here, molecular dispersion means uniform dispersion close to the molecular level. Paclitaxel microparticles of the present invention contain paclitaxel and a dispersion stabilizer. A paclitaxel microparticle dispersion liquid of the present invention is obtained by dispersing the paclitaxel microparticles of the present invention in water. A lyophilized material of the present invention is obtained by lyophilizing the paclitaxel microparticle dispersion liquid of the present invention. An orally administered formulation of the present invention contains the paclitaxel microparticles, the paclitaxel microparticle dispersion liquid, or the lyophilized material of the present invention. An injection formulation of the present invention contains a dispersion liquid obtained by redispersing the paclitaxel microparticles, the paclitaxel microparticle dispersion liquid, or the lyophilized material of the present invention in water. These can be manufactured by using the paclitaxel solid composition manufacturing method or paclitaxel microparticle dispersion liquid manufacturing method of the present invention, and have excellent safety and stability.
The present invention can provide a paclitaxel solid composition, paclitaxel microparticles, and a paclitaxel microparticle dispersion liquid, etc., which are improved in stability and safety.
Best modes for carrying out the present invention shall now be described in detail with reference to the drawings. In the description of the drawings, elements that are the same shall be provided with the same symbols and overlapping description shall be omitted.
In the embodiment described hereinafter, it is essential that paclitaxel is used as a poorly soluble drug, or polyvinylpyrrolidone and sodium lauryl sulfate are used as a dispersion stabilizer.
In the embodiment described below, “paclitaxel solid composition,” “paclitaxel microparticles,” and “paclitaxel microparticle dispersion liquid” are also referred to respectively as “solid composition,” “microparticles,” and “microparticle dispersion liquid,” simply.
(First Embodiment)
First, a first embodiment of the present invention shall be described.
The container 13 is for containing a liquid to be treated, and is composed of a material enabling transmission of a laser light L output from the laser light source 11, and is preferably composed of glass. The temperature controller 14 includes a constant temperature bath, a thermometer, and a temperature control unit, maintains the container 13 housed in the constant temperature bath and the liquid to be treated contained in the interior of the container 13 at a fixed temperature by feedback control by the thermometer and the temperature control unit. A portion of the constant temperature bath, through which the laser light L, output from the laser light source 11, passes, is configured as a transparent window. The laser light source 11 emits a laser light L toward the container 13, and preferably emits an infrared laser light L with a wavelength of no less than 900 nm. The irradiation light controller 12 adjusts both or either of an intensity and an irradiation duration of the laser light L emitted from the laser light source 11 and irradiated on the container 13.
A microparticle dispersion liquid manufacturing method of the first embodiment shall now be described along with a solid composition manufacturing method of the first embodiment.
In the dissolving step S1, the poorly soluble drug and the dispersion stabilizer are dissolved in a volatile organic solvent in the container 13. Here, the poorly soluble drug is a drug that hardly dissolves in water and although a solubility thereof is not restricted in particular, the solubility is preferably no more than 50 μg/mL at a temperature of 25° C. Commercially available drugs, such as cyclosporin, tacrolimus, nifedipine, nicardipine hydrochloride, phenytoin, digitoxin, diazepam, nitrofurantoin, benoxaprofen, griseofulvin, sulfathiazole, piroxicam, carbamazepine, phenacetin, tolbutamide, theophylline, griseofulvin, chloramphenicol, paclitaxel, camptothecine, cisplatin, daunorubicin, methotrexate, mitomycin C, docetaxel, vincristine, amphotericin B, nystatin, and clobetasone butyrate and other corticosteroids, and other new drug candidate substances under development can be cited as examples of the poorly soluble drug.
The dispersion stabilizer is preferably a polymer or a surfactant. The polymer is preferably a substance that is high in water solubility and is readily soluble in various organic solvents. Hydroxypropylmethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, sodium carboxymethylcellulose, cellulose acetate phthalate, and other cellulose derivatives, agar, gelatin, sodium alginate, polyvinylpyrrolidone, aminoalkylmethacrylate copolymer, methacrylic acid copolymer, carboxyvinyl polymer, polyvinyl alcohol, polyethylene glycol, etc., can be cited as examples of the polymer. The surfactant is preferably of low toxicity, and sodium lauryl sulfate, cholic acid, deoxycholic acid, polyoxyethylene sorbitan fatty acid ester, etc., can be cited as examples.
In particular, polyvinylpyrrolidone and sodium lauryl sulfate are preferably used as the dispersion stabilizer.
As the organic solvent, methanol, ethanol, propanol, and other alcohols, acetone, acetonitrile, methyl acetate, ethyl acetate, diethyl ether, etc., can be cited as examples, and methanol, ethanol, propanol, and other alcohols are more preferable.
In the solid composition forming step S2 following the dissolving step S1, the organic solvent contained in the solution obtained in the dissolving step S1 is removed by evaporation, and by the organic solvent removal, a solid composition 1 as a pellet-form residue is obtained and this solid composition 1 becomes fixed on an inner wall of the container 13. Here, the solid composition 1 obtained is constituted of a poorly soluble drug and a dispersion stabilizer being molecular-dispersed.
In the water injecting step S3 following the solid composition forming step S2, water 2 is injected into the interior of the container 13. By this water injection, the solid composition 1, fixed on the inner surface of the container 13, become immersed in the water 2 (see
In the present embodiment, because the laser light L is irradiated at high efficiency on the pellet-form solid composition 1 fixed on the inner wall of the container 13, the microparticle dispersion liquid can be manufactured at high efficiency in a short time. Also, because the microparticles are formed even with sufficient weak light irradiation to a degree at which multiphoton absorption processes do not occur, drug degradation and other problems can be suppressed.
Microparticles, containing the poorly soluble drug and the dispersion stabilizer, are manufactured from the microparticle dispersion liquid manufactured as described above. Also, lyophilized microparticles are manufactured by lyophilizing the microparticles. Furthermore, an orally administered formulation, containing the microparticle dispersion liquid, the microparticles, or the lyophilized microparticles, is manufactured, and an injection formulation containing a dispersion liquid obtained by redispersing the microparticle dispersion liquid, the microparticles, or the lyophilized microparticles in water, is manufactured.
Preferably in the microparticle dispersion liquid preparing step S4, the laser light L is irradiated from outside a region of the inner wall of the container 13 on which the solid composition 1 is fixed as shown in
Preferably in the microparticle dispersion liquid preparing step S4, laser light L of a wavelength of no less than 900 nm is irradiated on the solid composition 1 from the laser light source 11. By the laser light L of such a wavelength being irradiated on the solid composition 1, photodegradation of the drug contained in the solid composition 1 can be suppressed further. Also, because the laser light L arrives at the interface via the solid composition 1 and the microparticles are formed at the interface, laser light L of a wavelength of low absorbance with respect to the solid composition 1 is preferably irradiated on the solid composition 1. Specifically, laser light L of a wavelength with which the absorbance with respect to the solid composition 1 is no more than approximately 0.01 is preferably irradiated on the solid composition 1.
Preferably in the microparticle dispersion liquid preparing step S4, both or either of the intensity and the duration of light irradiation on the solid composition 1 are or is adjusted by the irradiation light controller 12, and in this case, it becomes possible to control a particle diameter of the microparticles formed by the light irradiation. Preferably during the light irradiation on the solid composition 1, the irradiated region or the interior of the container is maintained at a fixed temperature by the temperature controller 14, and in this case, the particle diameter of the microparticles formed by the light irradiation is stabilized.
Preferably a sealed container is used as the container 13, and the dissolving step S1, the solid composition forming step S2, the water injecting step S3, and the microparticle dispersion liquid preparing step S4 are performed in a sterilized state. Or, the dissolving step S1 may be performed under a non-sterilized state and after filter sterilization of the solution, the solid composition forming step S2, the water injecting step S3, and the microparticle dispersion liquid preparing step S4 may be performed in a sterilized state. That is, because the present embodiment provides a simple method of simply irradiating light from the exterior of the container 13, it can be put into practice even in a sealed container and an injectable product can also be manufactured readily in a sterilized state.
The above-described solid composition, microparticles, microparticle dispersion liquid, lyophilized material, oral administrated formulation, and injection formulation when polyvinylpyrrolidone and sodium lauryl sulfate are used as a dispersion stabilizer are respectively excellent in solubility and absorbability as shown in the examples described later.
The above-described paclitaxel solid composition, paclitaxel microparticles, paclitaxel microparticle dispersion liquid, lyophilized material, oral administrated formulation, and injection formulation when paclitaxel is used as a poorly soluble drug are respectively excellent in safety because they contain paclitaxel as a poorly soluble drug and a low-toxic dispersion stabilizer. As shown in the examples described later, these are also excellent in stability.
(Second Embodiment)
A second embodiment of the present invention shall now be described. In comparison with the first embodiment, in the second embodiment, the dissolving step S1, the solid composition forming step S2, and the water injecting step S3 are the same, however, the microparticle dispersion liquid preparing step S4 is different. That is, although optical energy is applied to the solid composition 1 in the microparticle dispersion liquid preparing step S4 in the first embodiment, in the microparticle dispersion liquid preparing step S4 in the second embodiment, vibration (preferably, ultrasonic vibration) energy is applied to the solid composition 1 and the solid composition 1 is pulverized and made into microparticles, and a microparticle dispersion liquid, constituted of the microparticles being dispersed in the water 2, is thereby manufactured.
In the microparticle dispersion liquid preparing step S4 in the second embodiment, an ultrasonic probe as a vibrating unit for applying vibration energy to the solid composition 1 is immersed in the water 2 in the container 13, and ultrasonic vibration generated from this ultrasonic probe is applied to the solid composition 1. Or, as a vibrating unit, an ultrasonic generator is attached to the outer wall of the container 13 and ultrasonic vibration generated from this ultrasonic generator is applied to the solid composition 1. Or, the container 13 is put into an ultrasonic cleaner as a vibrating unit, and ultrasonic vibration is applied to the solid composition 1 from this ultrasonic cleaner. Or, the container 13 is put into a test tube mixer as a vibrating unit, and vibration is applied to the solid composition 1 from this test tube mixer.
In all of these cases, vibration energy is applied to the solid composition 1, and accordingly, the solid composition 1 is made into microparticles having the most thermally stable structure in water, and a microparticle dispersion liquid, constituted of the microparticles being dispersed in the water 2, is thereby manufactured. Thus, in the present embodiment in the case where polyvinylpyrrolidone and sodium lauryl sulfate are used as a dispersion stabilizer, microparticles and a microparticle dispersion liquid, etc., which are improved in solubility and absorbability can also be manufactured.
In the present embodiment in the case where paclitaxel is used as a poorly soluble drug, paclitaxel microparticles and a paclitaxel microparticle dispersion liquid, etc., which are improved in stability and safety can also be manufactured.
(Third Embodiment)
A third embodiment of the present invention shall now be described. In comparison with the first embodiment, in the third embodiment, the dissolving step S1, the solid composition forming step S2, and the water injecting step S3 are the same, however, the microparticle dispersion liquid preparing step S4 is different. That is, although optical energy is applied to the solid composition 1 in the microparticle dispersion liquid preparing step S4 in the first embodiment, in the microparticle dispersion liquid preparing step S4 in the third embodiment, the water 2 in the container 13 is stirred to apply energy to the solid composition 1, and the solid composition 1 is made into microparticles having the most thermally stable structure in water, and a microparticle dispersion liquid, constituted of the microparticles being dispersed in the water 2, is thereby manufactured.
In the microparticle dispersion liquid preparing step S4 in the third embodiment, a magnetic stirrer is used as a stirring unit for stirring the water 2 in the container 13, and by rotation of this magnetic stirrer, the water 2 in the container 13 is stirred. Or, as a stirring unit, a test tube mixer is used, and by vibration of this test tube mixer, the water 2 in the container 13 is stirred. The test tube mixer acts as a vibrating unit when the amount of water 2 in the container 13 is large, however, when the amount of water 2 in the container 13 is small, it acts as a stirring unit.
In all of these cases, energy is applied to the solid composition 1 by stirring the water 2 in the container 13, and the solid composition 1 is made into microparticles having the most thermally stable structure in water, and a microparticle dispersion liquid, constituted of the microparticles being dispersed in the water 2, is thereby manufactured. Thus, in the present embodiment in the case where polyvinylpyrrolidone and sodium lauryl sulfate are used as a dispersion stabilizer, microparticles and a microparticle dispersion liquid, etc., which are improved in solubility and absorbability can also be manufactured. In the present embodiment in the case where paclitaxel is used as a poorly soluble drug, paclitaxel microparticles and a paclitaxel microparticle dispersion liquid, etc., which are improved in stability and safety can also be manufactured.
A detailed Example 1A of a solid composition and a microparticle dispersion liquid of the present embodiment shall now be described. In Example 1A described below, cyclosporin A was used as a poorly soluble drug, and a microparticle dispersion liquid in which microparticles containing cyclosporin A, polyvinylpyrrolidone, and sodium lauryl sulfate were dispersed in water was manufactured. All following operations were carried out under room temperature (20° C.).
Cyclosporin A bulk powder (10 mg) as a poorly soluble drug, and polyvinylpyrrolidone (50 mg) and sodium lauryl sulfate (2 mg) as a dispersion stabilizer were placed in a test tube and dissolved in ethanol (1 mL), which is a volatile organic solvent. Under reduced pressure conditions, ethanol was dried, and a solid composition in which the drug (cyclosporin A) and the dispersion stabilizer (polyvinylpyrrolidone and sodium lauryl sulfate) were uniformly molecular-dispersed was thereby obtained. The solid composition thus obtained was hermetically sealed upon adding water to the test tube.
Nd:YAG pulse laser light was irradiated on the solid composition in the test tube from the lateral side of the test tube. Irradiation conditions were a wavelength of 1064 nm, an irradiation light intensity of 0.61 J/cm2/pulse, a pulse width of 5 to 7 ns, and a repetition frequency of 10 Hz. After 10 minutes of irradiation, a uniformly cloudy dispersion liquid A was obtained upon shaking gently.
Also, ultrasonic vibration was applied to the solid composition in the test tube. The apparatus used was a desktop ultrasonic cleaner B5510 (manufactured by Branson Ultrasonics Corp.), and the treatment conditions were 180 J/sec (42 kHz). After the treatment for 10 minutes, a uniformly cloudy dispersion liquid B was obtained.
Furthermore, the solid composition in the test tube was vibrated and stirred. The apparatus used was a test tube mixer HM-10H (manufactured by As One Corp.). After the treatment for 10 minutes, a uniformly cloudy dispersion liquid C was obtained.
A cyclosporin A amount contained in the obtained microparticle dispersion liquid was quantified by measuring an absorbance at a wavelength of210 nm by using high performance liquid chromatography (hereinafter referred to as “HPLC”). All the dispersion liquids A to C obtained according to each of the three energy applying methods showed a concentration of 9 to 10 mg/mL in the HPLC quantification.
Particle diameter distributions of these dispersion liquids A to C were measured.
As described above, it was possible to prepare a microparticle dispersion liquid, in which cyclosporin A microparticles were dispersed according to each of the three energy applying methods of laser light irradiation, vibration (including ultrasonic vibration), and stirring. Sedimentation was hardly observed even when all the dispersion liquids A to C obtained were left to stand still at room temperature for several days. Furthermore, lyophilization of these microparticle dispersion liquids A to C was possible, and significant differences in the electron microscopy image were not observed between the state before lyophilization and a resuspended dispersion liquid.
A more detailed example 2A of the solid composition and the microparticle dispersion liquid of the present embodiment will now be described. In the present Example 2A described hereinafter, clobetasone butyrate was used as the poorly soluble drug and a microparticle dispersion liquid in which microparticles containing clobetasone butyrate, polyvinylpyrrolidone, and sodium lauryl sulfate were dispersed in water, was manufactured. All following operations were carried out under room temperature (20° C.).
Clobetasone butyrate bulk powder (10 mg) as the poorly soluble drug and polyvinylpyrrolidone (50 mg) and sodium lauryl sulfate (2 mg) as the dispersion stabilizer were placed in a test tube and dissolved in ethanol (1 mL), which is a volatile organic solvent. The ethanol was dried under reduced pressure conditions to obtain a solid component in which the drug (clobetasone butyrate) and the dispersion stabilizer (polyvinylpyrrolidone and sodium lauryl sulfate) were molecular-dispersed uniformly. The solid composition thus obtained was hermetically sealed upon adding water to the test tube.
Nd:YAG pulse laser light was irradiated on the solid composition in the test tube from the lateral side of the test tube.
Irradiation conditions were a wavelength of 1064 nm, an irradiation light intensity of 0.61 J/cm2/pulse, a pulse width of 5 to 7 ns, and a repetition frequency of 10 Hz. After 10 minutes of irradiation, a uniformly cloudy dispersion liquid D was obtained upon shaking gently.
Also, ultrasonic vibration was applied to the solid composition in the test tube. The apparatus used was a desktop ultrasonic cleaner B5510 (manufactured by Branson Ultrasonics Corp.), and the treatment conditions were 180 J/sec (42 kHz). After the treatment for 10 minutes, a uniformly cloudy dispersion liquid E was obtained.
Furthermore, the solid composition in the test tube was vibrated and stirred. The apparatus used was a test tube mixer HM-10H (manufactured by As One Corp.). After the treatment for 10 minutes, a uniformly cloudy dispersion liquid F was obtained.
A clobetasone butyrate amount contained in the obtained microparticle dispersion liquid was quantified by measuring an absorbance at a wavelength of 240 nm by using HPLC. The dispersion liquids D to F obtained according to each of the three energy applying methods showed a concentration of 9 to 10 mg/mL in the HPLC quantification.
Particle diameter distributions of these dispersion liquids D to F were measured.
As described above, it was possible to prepare a microparticle dispersion liquid, in which clobetasone butyrate microparticles are dispersed according to each of the three energy applying methods of laser light irradiation, vibration (including ultrasonic vibration), and stirring. Sedimentation was hardly observed even when all the dispersion liquids D to F were left to stand still at room temperature for several days. Lyophilization of all these microparticle dispersion liquids D to F obtained was possible, and significant differences in the electron microscopy image were not observed between the state before lyophilization and a resuspended dispersion liquid.
A more detailed example of the paclitaxel solid composition and the paclitaxel microparticle dispersion liquid shall now be described.
In the present example described below, all following operations were carried out under room temperature (20° C.).
Paclitaxel bulk powder (10 mg) as a poorly soluble drug, and polyvinylpyrrolidone (50 mg) and sodium lauryl sulfate (2 mg) as a dispersion stabilizer were placed in a test tube and dissolved in ethanol (1 mL), which is a volatile organic solvent. Under reduced pressure conditions, ethanol was dried, and a paclitaxel solid composition in which the drug (paclitaxel) and the dispersion stabilizer (polyvinylpyrrolidone and sodium lauryl sulfate) were uniformly molecular-dispersed was thereby obtained. The paclitaxel solid composition thus obtained was hermetically sealed upon adding water to the test tube.
Nd:YAG pulse laser light was irradiated on the paclitaxel solid composition in the test tube from the lateral side of the test tube. Irradiation conditions were a wavelength of 1064 nm, an irradiation light intensity of 0.61 J/cm2/pulse, a pulse width of 5 to 7 ns, and a repetition frequency of 10 Hz. After 10 minutes of irradiation, a substantially colorless transparent paclitaxel microparticle dispersion liquid was obtained upon shaking gently.
A paclitaxel amount contained in the obtained paclitaxel microparticle dispersion liquid was quantified by measuring an absorbance at a wavelength of 227 nm by using high performance liquid chromatography (hereinafter referred to as “HPLC”).
As shown in these drawings, paclitaxel was eluted at a position of approximately 8 minutes, and as a result of comparing and calculating the paclitaxel amount in the sample based on the peak area obtained by measuring the reference preparation, the paclitaxel amount in the paclitaxel microparticle dispersion liquid was found to be 9.80 mg/mL (n=3). It was thus possible to prepare a paclitaxel microparticle dispersion liquid with a sufficiently high concentration approximately 20,000 times as high as the solubility (approximately 0.5 μg/mL) of paclitaxel in water. On the HPLC chart, the impurity peak is approximately one several hundredths to one several thousandths of the principal agent peak, and an increase in the impurity peak due to laser light irradiation was not observed.
A particle diameter distribution of the obtained paclitaxel microparticle dispersion liquid was measured by using a measuring apparatus for particle size distribution SALD-7000 (manufactured by Shimadzu Corp.). Furthermore, an electron microscopic image (SEM) of microparticles contained in the paclitaxel microparticle dispersion liquid was observed by using a scanning electron microscope S4200 (manufactured by Hitachi, Ltd.). However, neither of the particle diameter distribution (measurement limit<approximately 100 nm) nor the electron microscopic image (measurement limit<approximately 50 nm) could be observed. The reason for this is considered that the particle diameter is less than the measurement limit.
The obtained paclitaxel microparticle dispersion liquid was high in stability, and even after 12 hours elapsed, still had a stably high concentration of 10 mg/mL and was a still substantially colorless and transparent dispersion liquid, and no precipitate was observed.
| Number | Date | Country | Kind |
|---|---|---|---|
| P2007-259094 | Oct 2007 | JP | national |
| P2007-259102 | Oct 2007 | JP | national |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12235825 | Sep 2008 | US |
| Child | 13217687 | US |
